

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/627,882
Filing Date	July 25, 2003
First Named Inventor	PARK, Jong-Gu
Art Unit	1634
Examiner Name	JAMES MARTINELL
Attorney Docket Number	57354-11USA

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	ISAKA Y et al., "Transforming growth factor-beta1 antisense oligodeoxynucleotides block interstitial fibrosis in unilateral ureteral obstruction," KIDNEY INTERNATIONAL, 58(5):1885-1892 (2000).	<input type="checkbox"/>
	C2	ISAKU Y, "Application of gene therapy to kidney diseases," CLINICAL AND EXPERIMENTAL NEPHROLOGY, 3:147-153 (1999).	
	C3	ANDO Y et al., "Introduction of TGF-beta antisense oligodeoxy-nucleotides (ODN) into interstitial fibroblast blocked tubulointerstitial fibrosis in unilateral ureter obstruction (UUO) rats," JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 9: 512A (1998).	
	C4	AKAGI Y et al., "Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis," KIDNEY INTERNATIONAL 50(1) 148-155 (1996).	
	C5	MOON et al., "Potent growth inhibition of leukemic cells by novel ribbon-type antisense oligonucleotides to c-mycb1," THE JOURNAL OF BIOLOGICAL CHEMISTRY, 275(7): 4647-4653 (2000).	
	C6	MOON et al., "Target site search and effective inhibition of leukaemic cell growth by a covalently closed multiple anti-sense oligonucleotide to c-mycb," BIOCHEM. J., 346:295-303 (2000).	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.